Abstract
Abstract
Background: Cisplatin is an effective anticancer drug, but its use is associated with adverse effects, including bone marrow suppression and hematological toxicity. Angiotensin II receptor blockers (ARBs) have been suggested to possess protective effects against tissue injury through their anti-inflammatory and antioxidant properties.
Objective: To evaluate and compare the potential myeloprotective effects of azilsartan and olmesartan against cisplatin-induced myelosuppression in mice.
Method: Swiss albino mice were divided into experimental groups receiving azilsartan or olmesartan, with or without cisplatin, alongside appropriate control groups. Azilsartan and olmesartan were administered orally, while cisplatin was administered intraperitoneally to induce myelosuppression. Hematological parameters were assessed, and bone marrow samples were collected for evaluation of inflammatory and oxidative-stress markers. Gene expression of TNF-α, IL-1β, and IL-10 was assessed by qPCR, while SOD, MDA, and GSH levels were evaluated by ELISA. The expression of Bax and Bcl-2 was assessed by Western blotting.
Results: Cisplatin administration produced evidence of bone marrow suppression, including reductions in hematological parameters. Treatment with azilsartan and olmesartan showed potential protective effects against cisplatin-induced hematological and molecular alterations. Changes in inflammatory, oxidative-stress, and apoptosis-related markers were observed in the treated groups compared with the cisplatin group.
Conclusion: The findings suggest that azilsartan and olmesartan may have potential myeloprotective effects against cisplatin-induced myelosuppression in mice. Their protective effects may involve modulation of inflammatory responses, oxidative stress, and apoptosis. Further studies with larger sample sizes and detailed mechanistic evaluation are warranted
| Intend to be published in the IJPS ? | NO |
|---|---|
| Has the manuscript been published | not published |
